Update on the appropriate use of linezolid in clinical practice

References

• AbbanatDMacielagMBushKNovel antibacterial agents for the treatment of serious Gram-positive infectionsExpert Opin Investig Drugs20031237999
   PubMed Web of Science ®Google Scholar
• AkinsRLHaaseKKGram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases PharmacistsPharmacotherapy20052510011016006278
   PubMed Web of Science ®Google Scholar
• AlcalaLRuiz-SerranoMJPérez-Fernandez-TuréganoCIn vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugsAntimicrob Agents Chemother2003474161712499228
   PubMed Web of Science ®Google Scholar
• AndereggTRSaderHSFritscheTRTrends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox annual appraisal of potency and spectrum (ZAAPS) programInt J Antimicrob Agents200526132115967640
   PubMed Web of Science ®Google Scholar
• AnonymousReduced susceptibility of Staphylococcus aureus to vancomycin – Japan 1996MMWR19974662469218648
   PubMedGoogle Scholar
• BarberanJManagement of infections of osteoarticular prosthesisClin Microbiol Infect200612Suppl. 39310116669932
   PubMed Web of Science ®Google Scholar
• BirminghamMCRaynerCRMeagherAKLinezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use programClin Infect Dis2003361596812522747
   PubMed Web of Science ®Google Scholar
• BisharaJPitlikSSamraZCo-trimoxazole sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988–1997Emerg Infect Dis200391168914519258
   PubMed Web of Science ®Google Scholar
• BresslerAMZimmerSMGilmoreJLPeripheral neuropathy associated with prolonged use of linezolidLancet Infect Dis200445283115288827
   PubMed Web of Science ®Google Scholar
• CastroPSorianoAEschrichCLinezolid treatment of ventriculoperitoneal shunt infection without implant removalEur J Clin Microbiol Infect Dis200524603616187055
   PubMed Web of Science ®Google Scholar
• ClarkDBAndrusMRByrdDCDrug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literaturePharmacotherapy2006262697616466332
   PubMed Web of Science ®Google Scholar
• CravenDEPalladinoRMcQuillenDPHealthcare-associated pneumonia in adults: management principles to improve outcomesInfect Dis Clin North Am2004189396215555833
   PubMed Web of Science ®Google Scholar
• CuevasOCercenadoEVindelAEvolution of antimicrobial resistance of Staphylococcus spp. In Spain: five nationwide prevalence studies, 1986 to 2002Antimicrob Agents Chemother2004484240515504847
   PubMed Web of Science ®Google Scholar
• CunhaBAMethicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapyClin Microbiol Infect200511Suppl. 4334215997484
   PubMedGoogle Scholar
• EdmondMBWallaceSEMcClishDKNosocomial bloodstream infections in United States hospitals. A three-year analysisClin Infect Dis1999292394410476719
   PubMed Web of Science ®Google Scholar
• EliopoulosGMQuinupristin/dalfopristin and linezolid: evidence and opinionsClin Infect Dis2003364738112567306
   PubMed Web of Science ®Google Scholar
• EllisMWLewisJS2ndTreatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infectionsCurr Opin Infect Dis20051849650116258322
   PubMed Web of Science ®Google Scholar
• ErturanZUzunMIn vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolatesInt J Antimicrob Agents200526788015950439
   PubMed Web of Science ®Google Scholar
• FiaccadoriEMaggioreURotelliCRemoval of linezolid by conventional intermittent hemodyalisis, sustained low-efficiency dyalisis, or continuous venovenous hemofiltration in patients with acute renal failureCrit Care Med20043224374215599148
   PubMed Web of Science ®Google Scholar
• FortunJMartin-DavillaPNavasELinezolid for the treatment of multidrug-resistant tuberculosisJ Antimicrob Chemother200556180515911549
   PubMed Web of Science ®Google Scholar
• Garcia-RocaPMancilla-RamirezJSantos-SeguraALinezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cellsArch Med Res20063731516314183
   PubMed Web of Science ®Google Scholar
• HancockREMechanism of action of newer antibiotics for Gram-positive pathogensLancet Infect Dis200552091815792738
   PubMed Web of Science ®Google Scholar
• HerreroIAIssaNCPatelRNosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faeciumN Engl J Med2002346867911893808
   PubMed Web of Science ®Google Scholar
• HillEEHerijgersPHerregodsMCInfective endocarditis treated with linezolid: case report and literature reviewEur J Clin Microbiol Infect Dis200625202416525776
   PubMed Web of Science ®Google Scholar
• HsuehPRChenWHTengLJNosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a University Hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agentsInt J Antimicrob Agents20052643915975769
   PubMed Web of Science ®Google Scholar
• JonesRNRossJEFritscheTROxazolidinone susceptibility patterns in 2004: report from the Zyvox annual appraisal of potency and spectrum (ZAAPS) Program assessing isolates from 16 nationsJ Antimicrob Chemother2006572798716326811
   PubMed Web of Science ®Google Scholar
• KarchmerAWNosocomial bloodstream infections: organisms, risk factors, and implicationsClin Infect Dis200031Suppl. 4S1394311017863
   PubMed Web of Science ®Google Scholar
• KollefMHAntibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infectionEur J Clin Microbiol Infect Dis20052479480316341681
   PubMed Web of Science ®Google Scholar
• KopteridesPPapadomichelakisEArmaganidisALinezolid use associated with lactic acidosisScand J Infect Dis200537153415764207
   PubMed Web of Science ®Google Scholar
• LadhaniSGarbashMStaphylococcal skin infections in children: rational drug therapy recommendationsPaediatr Drugs200577710215871629
   PubMedGoogle Scholar
• LambHMFiggittDPFauldsDQuinupristin/dalfopristin: a review of its use in the management of serious gram-positive infectionsDrugs19995810619710651391
   PubMed Web of Science ®Google Scholar
• LaPlanteKLRybakMJDaptomycin – a novel antibiotic against Gram-positive pathogensExp Opin Pharmacother20045232131
   PubMed Web of Science ®Google Scholar
• LawrenceKRAdraMGillmanPKSerotonin toxicity with the use of linezolid: a review of postmarketing dataClin Infect Dis20064215788316652315
   PubMed Web of Science ®Google Scholar
• LindenPKTreatment options for vancomycin-resistant enterococcal infectionsDrugs2002624254111827558
   PubMed Web of Science ®Google Scholar
• LipskyBAItaniKNordenCTreating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanateClin Infect Dis200438172414679443
   PubMed Web of Science ®Google Scholar
• ManfrediRNanettiAMorelliSSensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antimicrobial agents other than beta-lactams: profile and trend, 1998–2003Isr Med Assoc J20046191215055283
   PubMed Web of Science ®Google Scholar
• ManfrediRSabbataniSChiodoFSevere staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: a case report and literature reviewScand J Infect Dis2005375131716012016
   PubMed Web of Science ®Google Scholar
• ManfrediRSabbataniSMarinacciGListeria monocytogenes meningitis and multiple brain abscesses in an immunocompetent host. Favorable response to combined linezolid treatmentJ Chemother200618331317129848
   PubMed Web of Science ®Google Scholar
• MarcinakJFFrankALEpidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in childrenExpert Rev Anti Infect Ther200649110016441212
   PubMedGoogle Scholar
• MarshallSAWilkeWWPfallerMAStaphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE programDiagn Microbiol Infect Dis199830205149572028
   PubMed Web of Science ®Google Scholar
• MekaVGGoldHSAntimicrobial resistance to linezolidClin Infect Dis2004391010515472854
   PubMed Web of Science ®Google Scholar
• MenichettiFCurrent and emerging serious Gram-positive infectionsClin Microbiol Infect200511Suppl. 322815811021
   PubMedGoogle Scholar
• MoelleringRCJrLinezolid: the first oxazolidinone antimicrobialAnn Intern Med20031381354212529096
   PubMed Web of Science ®Google Scholar
• NasrawaySAShorrAFKuterDJLinezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin useClin Infect Dis20033716091614689341
   PubMed Web of Science ®Google Scholar
• NathwaniDLiJZBalanDAAn economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effectsInt J Antimicrob Agents2004233152415081078
   PubMed Web of Science ®Google Scholar
• NathwaniD2006 Personal communication
   Google Scholar
• NicolettiGBonfiglioGBartoloniADistribution and antibiotic resistance of isolates from lower respiratory tract and blood cultures from patients in three Italian intensive care units: a 2-year comparisonInt J Antimicrob Agents200015265910929875
   PubMed Web of Science ®Google Scholar
• PaceJLYangGGlycopeptides: update on an old successful antibiotic classBiochem Pharmacol2006719688016412985
   PubMed Web of Science ®Google Scholar
• RobertsSChambersSDiagnosis and management of Staphylococcus aureus infections of the skin and soft tissueIntern Med J200535Suppl. 2S9710516271065
   PubMedGoogle Scholar
• Rodriguez DiazJCRuizMLopezMSynergistic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosisInt J Antimicrob Agents200321354612672583
   PubMed Web of Science ®Google Scholar
• RubinsteinECammarataSOliphantTLinezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind multicenter studyClin Infect Dis2001324021211170948
   PubMed Web of Science ®Google Scholar
• RubinsteinEIsturizRStandifordHCWorldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled Phase III studiesAntimicrob Agents Chemother20034718243112760854
   PubMed Web of Science ®Google Scholar
• SabbataniSManfrediRFrankGLinezolid in the treatment of central nervous system infections resistant to recommended antimicrobial compoundsInfez Med2005131121916220032
   PubMedGoogle Scholar
• SalyersAAGuptaAWangYHuman intestinal bacteria as reservoirs for antibiotic resistance genesTrends Microbiol2004124121615337162
   PubMed Web of Science ®Google Scholar
• Schmidt–IoanasMDe RouxALodeHNew antibiotics for the treatment of severe staphylococcal infection in the critically ill patientCurr Opin Crit Care200511481616175036
   PubMed Web of Science ®Google Scholar
• SegretiJEfficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistanceClin Microbiol Infect200511Suppl. 3293515811022
   PubMed Web of Science ®Google Scholar
• SennevilleELegoutLValetteMRisk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control studyJ Antimicrob Chemother200556440115956097
   PubMedGoogle Scholar
• ShahPMThe need for new therapeutic agents: what is the pipeline?Clin Microbiol Infect200511Suppl. 3364215900655
   PubMedGoogle Scholar
• SharpeJNShivelyEHPolkHCJrClinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower extremity skin and soft tissue infections caused by methicillin-resistant Staphyloccus aureusAm J Surg2005189425815820454
   PubMed Web of Science ®Google Scholar
• SmithPFBookerBMOgundeleABComparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer centerDiagn Microbiol Infect Dis200552255915935606
   PubMed Web of Science ®Google Scholar
• SolaCLBostwickJMHartDAAnticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguiseMayo Clin Proc200681330416529136
   PubMed Web of Science ®Google Scholar
• StevensDLDotterBMadaras-KellyAA review of linezolid: the first oxazolidinone antibioticExpert Rev Anti-Infective Ther20042519
   PubMedGoogle Scholar
• TsujiBTRybakMJEtest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycinDiagn Microbiol Infect Dis20065473716368477
   PubMed Web of Science ®Google Scholar
• WeigeltJItaniKStevensDLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother2005492260615917519
   PubMed Web of Science ®Google Scholar
• WenzelRPEdmondMBVancomycin-resistant Staphylococcus aureus: infection control considerationsClin Infect Dis19982724599709870
   PubMed Web of Science ®Google Scholar
• WilcoxMNathwaniDDrydenMLinezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infectionsJ Antimicrob Chemother2004533354214729745
   PubMed Web of Science ®Google Scholar
• WunderinkRGCammarataSKOliphantTHContinuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumoniaClin Ther2003259809212852712
   PubMed Web of Science ®Google Scholar